![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JH Harrison , DG Hoyt and JS Lazo
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06510.
The severity of bleomycin (BLM)-induced pulmonary fibrosis in mice varies markedly among several different murine strains. We have examined the DNA from lungs of sensitive (i.e., C57BL/6N) and resistant (i.e., BALB/c) strains of mice using a nucleoid sedimentation technique to detect early in vivo changes in the integrity of DNA after intravenous BLM. Mice received intravenous injections of BLM (80 mg/kg) or vehicle; lung nucleoids were prepared 15 min to 6 hr later. BLM produced striking decreases in nucleoid sedimentation distance versus paired controls in both strains within 15 min after injection, indicating extensive DNA scission. Repair of DNA strand breaks was complete in the resistant (BALB/c) mice by 5 hr; in contrast, only partial repair occurred in the sensitive (C57BL/6N) strain during that time. We then examined lungs for subsequent changes in steady state poly-(A)+ RNA levels and mRNA levels for lung matrix proteins (type I procollagen, type III procollagen, and fibronectin). Steady state levels of poly-(A)+ RNA were depressed to 50% of control 1 through 6 days after BLM injection in the lungs of sensitive mice. Resistant mice had pulmonary poly-(A)+ RNA levels similar to those of C57BL/6N mice, except for a 2-fold elevation 1 day after BLM injection. BLM injection affected the steady state levels of mRNA encoding lung matrix proteins differently than total poly-(A)+ RNA. Fibronectin mRNA/poly(A)+ RNA was elevated 2-fold 1 day after BLM treatment only in the sensitive strain and remained elevated at 3 and 6 days. In contrast, alpha 2I procollagen mRNA increased in both murine strains and alpha 1III procollagen mRNA decreased in both strains. Thus, a 7-fold or greater increase in the type I: type III procollagen mRNA ratio was seen in both strains 3 to 6 days after BLM injection. These data demonstrate that BLM treatment rapidly produces extensive pulmonary DNA damage in vivo, that persistence of DNA damage rather than the initial level of strand scission is associated with sensitivity to BLM lung disease in these mice, and that changes in the levels of mRNA encoding pulmonary matrix proteins occur in vivo within 1 to 3 days after intravenous BLM treatment.
This article has been cited by other articles:
|
|
 |
|
  A. Serrano-Mollar, M. Nacher, G. Gay-Jordi, D. Closa, A. Xaubet, and O. Bulbena Intratracheal Transplantation of Alveolar Type II Cells Reverses Bleomycin-induced Lung Fibrosis Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1261 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Xu, A. L. Mora, J. LaVoy, K. L. Brigham, and M. Rojas Increased bleomycin-induced lung injury in mice deficient in the transcription factor T-bet Am J Physiol Lung Cell Mol Physiol, October 1, 2006; 291(4): L658 - L667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Garipidou, S. Vakalopoulou, E. Zafiriadou, V. Kaloutsi, K. Tziomalos, and V. Perifanis Uncommon manifestation of bleomycin-induced pulmonary toxicity in a patient with Hodgkin's disease Ann. Onc., March 1, 2005; 16(3): 514 - 515. [Full Text] [PDF]
|
|
|
|
|
|
I. Inoshima, K. Kuwano, N. Hamada, M. Yoshimi, T. Maeyama, N. Hagimoto, Y. Nakanishi, and N. Hara Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, April 1, 2004; 286(4): L727 - L733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Ortiz, F. Gambelli, C. McBride, D. Gaupp, M. Baddoo, N. Kaminski, and D. G. Phinney Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects PNAS, July 8, 2003; 100(14): 8407 - 8411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghosh, T. Mendoza, L. A. Ortiz, G. W. Hoyle, C. D. Fermin, A. R. Brody, M. Friedman, and G. F. Morris Bleomycin Sensitivity of Mice Expressing Dominant-Negative p53 in the Lung Epithelium Am. J. Respir. Crit. Care Med., September 15, 2002; 166(6): 890 - 897. [Abstract] [Full Text]
|
|
|
|
|
|
T. Maeyama, K. Kuwano, M. Kawasaki, R. Kunitake, N. Hagimoto, and N. Hara Attenuation of bleomycin-induced pneumopathy in mice by monoclonal antibody to interleukin-12 Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1128 - L1137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kuwano, R. Kunitake, T. Maeyama, N. Hagimoto, M. Kawasaki, T. Matsuba, M. Yoshimi, I. Inoshima, K. Yoshida, and N. Hara Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor Am J Physiol Lung Cell Mol Physiol, February 1, 2001; 280(2): L316 - L325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Savani, G. Hou, P. Liu, C. Wang, E. Simons, P. C. Grimm, R. Stern, A. H. Greenberg, H. M. DeLisser, and N. Khalil A Role for Hyaluronan in Macrophage Accumulation and Collagen Deposition after Bleomycin-Induced Lung Injury Am. J. Respir. Cell Mol. Biol., October 1, 2000; 23(4): 475 - 484. [Abstract] [Full Text]
|
|
|
|
|
|
X. Y. ZHANG, S. SHIMURA, T. MASUDA, H. SAITOH, and K. SHIRATO Antisense Oligonucleotides to NF-kappa B Improve Survival in Bleomycin-induced Pneumopathy of the Mouse Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1561 - 1568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mishra, N. A. Doyle, and W. J. Martin II Bleomycin-Mediated Pulmonary Toxicity . Evidence for a p53-Mediated Response Am. J. Respir. Cell Mol. Biol., May 1, 2000; 22(5): 543 - 549. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kuwano and N. Hara Signal Transduction Pathways of Apoptosis and Inflammation Induced by the Tumor Necrosis Factor Receptor Family Am. J. Respir. Cell Mol. Biol., February 1, 2000; 22(2): 147 - 149. [Full Text]
|
|
|
|
|
|
L. A. Ortiz, J. A. Lasky, H. Safah, M. Reyes, A. Miller, G. Lungarella, and M. Friedman Exacerbation of bleomycin-induced lung injury in mice by amifostine Am J Physiol Lung Cell Mol Physiol, December 1, 1999; 277(6): L1239 - L1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Okudela, T. Ito, H. Mitsui, H. Hayashi, N. Udaka, M. Kanisawa, and H. Kitamura The Role of p53 in Bleomycin-Induced DNA Damage in the Lung : A Comparative Study with the Small Intestine Am. J. Pathol., October 1, 1999; 155(4): 1341 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Ortiz, K. Moroz, J.-Y. Liu, G. W. Hoyle, T. Hammond, R. F. Hamilton, A. Holian, W. Banks, A. R. Brody, and M. Friedman Alveolar macrophage apoptosis and TNF-alpha , but not p53, expression correlate with murine response to bleomycin Am J Physiol Lung Cell Mol Physiol, December 1, 1998; 275(6): L1208 - L1218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, S. L. Young, and J. C. McIntosh Induction of tenascin in rat lungs undergoing bleomycin-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, June 1, 1998; 274(6): L1049 - L1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Gram Chemically Reactive Intermediates and Pulmonary Xenobiotic Toxicity Pharmacol. Rev., December 1, 1997; 49(4): 297 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hagimoto, K. Kuwano, H. Miyazaki, R. Kunitake, M. Fujita, M. Kawasaki, Y. Kaneko, and N. Hara Induction of Apoptosis and Pulmonary Fibrosis in Mice in Response to Ligation of Fas Antigen Am. J. Respir. Cell Mol. Biol., September 1, 1997; 17(3): 272 - 278. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
